v3.22.2.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Revenue $ 76 $ 200 $ 265 $ 200
Operating expenses:        
Cost of revenue 1,626 144 1,996 144
Sales and marketing 4,736 2,293 13,559 5,555
General and administrative 10,320 6,109 30,982 16,314
Amortization of acquired intangible assets 505 17 1,278 23
Research and development 6,202 5,305 18,873 12,878
Total operating expenses 23,389 13,868 66,688 34,914
Net loss from operations (23,313) (13,668) (66,423) (34,714)
Other income (expense):        
Interest expense (525) (1,049)
Change in fair value - Senior Secured Convertible Notes and Senior Convertible Note 261 (1,739) 1,682
Loss on issue and offering costs - Senior Secured Convertible Note (1,232) (4,332)
Debt extinguishments loss - Senior Secured Convertible Notes (5,123) (5,123) (3,715)
Debt forgiveness 300
Other income (expense), net (6,619) (12,243) (1,733)
Loss before provision for income tax (29,932) (13,668) (78,666) (36,447)
Provision for income taxes
Net loss before noncontrolling interests (29,932) (13,668) (78,666) (36,447)
Net loss attributable to the noncontrolling interests 3,806 1,441 10,143 3,318
Net loss attributable to PAVmed Inc. (26,126) (12,227) (68,523) (33,129)
Less: Series B Convertible Preferred Stock dividends earned (71) (67) (209) (216)
Net loss attributable to PAVmed Inc. common stockholders $ (26,197) $ (12,294) $ (68,732) $ (33,345)
Per share information:        
Net loss per share attributable to PAVmed Inc. - basic and diluted $ (0.29) $ (0.15) $ (0.78) $ (0.41)
Net loss per share attributable to PAVmed Inc. common stockholders – basic and diluted $ (0.29) $ (0.15) $ (0.78) $ (0.42)
Weighted average common shares outstanding, basic and diluted 89,758,927 83,307,170 87,724,124 79,873,583

Source